Acadia Pharmaceuticals Inc said on Wednesday dementia patients taking its drug Nuplazid were nearly three times less prone to a psychotic relapse than those on placebo. The drugmaker’s late-stage trial testing Nuplazid, stopped in September after positive results, enrolled 392 patients aged 74.5 years on average. Patients on the drug experienced a 65% reduction rate in relapses of dementia-related psychotic episodes, the company said. …read more
Source:: Yahoo Finance
